Mental Health: Attention-Deficit/Hyperactivity Disorder, Bipolar Disorder, and Schizophrenia

1. Introduction

The pharmacological management of major psychiatric disorders represents a cornerstone of modern therapeutics, integrating complex neurobiological principles with clinical practice. This chapter focuses on three distinct yet diagnostically critical conditions: attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, and schizophrenia. Each disorder presents unique challenges in diagnosis, pathophysiology, and treatment, demanding a nuanced understanding from future clinicians and pharmacists. The historical evolution of treatments for these conditions, from early sedatives and lithium to contemporary atypical antipsychotics and targeted stimulants, reflects the progressive elucidation of central nervous system function. Mastery of this area is essential, as these disorders are prevalent, chronic, and associated with significant morbidity, impacting cognitive function, emotional regulation, and overall quality of life.

The importance in pharmacology and medicine is multifaceted. These conditions require long-term, often lifelong, pharmacotherapeutic strategies where the therapeutic index can be narrow and side effect burdens substantial. Pharmacokinetic and pharmacodynamic considerations are paramount, influencing dosing schedules, adherence, and outcomes. Furthermore, the management frequently involves complex polypharmacy, necessitating a sophisticated understanding of drug interactions and adverse effect profiles. The following learning objectives are designed to guide the acquisition of core competencies in this domain.

• Differentiate the core neurobiological hypotheses, diagnostic criteria, and symptomatic profiles of ADHD, bipolar disorder, and schizophrenia.
• Explain the proposed mechanisms of action for first-line pharmacological agents used in each disorder, linking molecular targets to clinical effects.
• Analyze the pharmacokinetic properties, major adverse effects, and monitoring requirements for key drug classes, including stimulants, mood stabilizers, and antipsychotics.
• Evaluate clinical presentation through case scenarios to formulate and justify appropriate pharmacotherapeutic plans, considering patient-specific factors.
• Identify major drug-drug interactions and management strategies for treatment-resistant cases or significant adverse drug reactions.

2. Fundamental Principles

Understanding the pharmacology of psychiatric disorders is predicated on several foundational concepts in neurobiology and diagnostic classification. These principles provide the framework for rational drug therapy.

2.1 Core Neurotransmitter Systems

The monoamine hypothesis forms a historical and still-relevant basis for understanding the pharmacotherapy of mood and psychotic disorders. This model implicates dysregulation in the dopaminergic, noradrenergic, and serotonergic pathways. Dopamine is particularly central, with its role in reward, motivation, executive function, and motor control. Hyperdopaminergic states in mesolimbic pathways are theorized to contribute to positive symptoms of schizophrenia, while hypodopaminergic activity in mesocortical pathways may underlie negative symptoms and cognitive deficits. Noradrenaline is involved in arousal, attention, and stress response, relevant to ADHD and mood disorders. Serotonin modulates mood, anxiety, impulse control, and sleep. The glutamatergic and GABAergic systems are also critically involved, representing the primary excitatory and inhibitory neurotransmitters in the brain, respectively. Dysfunction in glutamate signaling, particularly via N-methyl-D-aspartate (NMDA) receptors, is implicated in the cognitive and negative symptoms of schizophrenia.

2.2 Diagnostic Nosology and Spectrum Concepts

Accurate diagnosis precedes effective treatment. ADHD, bipolar disorder, and schizophrenia are defined by specific criteria in diagnostic manuals such as the DSM-5-TR or ICD-11. ADHD is characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity. Bipolar disorder is defined by episodic disturbances in mood, energy, and activity, encompassing manic, hypomanic, and depressive episodes. Schizophrenia involves a combination of positive symptoms (e.g., hallucinations, delusions), negative symptoms (e.g., avolition, alogia), and cognitive impairments. A spectrum conceptualization is increasingly recognized, particularly for bipolar disorder (bipolar I, II, cyclothymia) and schizophrenia (inclusion of schizoaffective disorder), which acknowledges variability in symptom presentation and severity.

2.3 Key Pharmacological Terminology

Specific terms are essential for discussing psychiatric pharmacology. Efficacy refers to the maximum therapeutic effect a drug can produce. Potency denotes the dose required to produce a given effect. Therapeutic index is the ratio between the toxic and therapeutic doses, a crucial consideration for drugs like lithium. Tolerance describes a reduced response to a drug after repeated administration. Tachyphylaxis is a rapid decrease in response. Extrapyramidal symptoms (EPS) are movement disorders associated with antipsychotic drugs. Kindling is a neurobiological process wherein repeated subthreshold stimuli lower the threshold for future episodes, a model relevant to bipolar disorder progression.

3. Detailed Explanation

An in-depth exploration of each disorder’s pathophysiology and corresponding pharmacotherapy reveals distinct mechanistic landscapes.

3.1 Attention-Deficit/Hyperactivity Disorder (ADHD)

The neurobiology of ADHD is associated with dysregulation in fronto-striatal-cerebellar circuits, which govern executive functions, attention, and behavioral inhibition. Neuroimaging studies frequently indicate reduced volume and activity in the prefrontal cortex, basal ganglia, and cerebellum. Catecholamine dysregulation, particularly of dopamine and noradrenaline in these regions, is a central hypothesis. The prefrontal cortex, vital for working memory and impulse control, is highly dependent on optimal levels of these neurotransmitters. Pharmacological agents aim to augment catecholaminergic signaling, primarily by blocking reuptake transporters or promoting release.

Mechanisms of First-Line Agents: Stimulant medications, methylphenidate and amphetamine derivatives, are the cornerstone of treatment. Methylphenidate primarily acts as a dopamine and noradrenaline reuptake inhibitor (DNRI), blocking the dopamine transporter (DAT) and noradrenaline transporter (NET). Amphetamines have a more complex mechanism: they are substrates for these transporters, entering the presynaptic neuron and inducing reverse transport of monoamines into the synapse while also inhibiting monoamine oxidase (MAO) and reuptake. Both actions lead to a significant increase in synaptic dopamine and noradrenaline. Non-stimulant options include atomoxetine, a selective noradrenaline reuptake inhibitor (NRI), and α₂-adrenergic agonists like guanfacine and clonidine, which enhance noradrenaline signaling via presynaptic and postsynaptic mechanisms to improve prefrontal cortical function.

Pharmacokinetic Considerations: Formulation technology critically impacts clinical use. Immediate-release (IR) stimulants have a rapid onset (≈30-60 minutes) and short duration (3-5 hours), often requiring multiple daily doses. Extended-release (ER) formulations use various technologies (e.g., osmotic release, bead systems) to provide a longer duration (8-12 hours), improving adherence and minimizing rebound symptoms. The bioavailability of oral stimulants is high but variable, and they undergo significant hepatic metabolism primarily via CYP2D6 (atomoxetine, some amphetamines) and esterases (methylphenidate).

3.2 Bipolar Disorder

Bipolar disorder is characterized by pathological shifts in mood, energy, and neurovegetative functions. The underlying pathophysiology involves disturbances in monoaminergic transmission, intracellular signaling cascades, neuroplasticity, and circadian rhythm regulation. The kindling model suggests that initial mood episodes may be triggered by psychosocial stressors, but over time, episodes become more frequent and may occur autonomously due to neurobiological sensitization. Mood stabilizers, the mainstay of treatment, are believed to exert effects on these downstream intracellular pathways rather than on neurotransmitter levels alone.

Mechanisms of Mood Stabilizers and Antipsychotics: Lithium’s mechanism, while not fully elucidated, involves inhibition of inositol monophosphatase, leading to reduced recycling of inositol and dampening of overactive phosphatidylinositol (PI) signaling. It also inhibits glycogen synthase kinase-3 beta (GSK-3β), which influences neuroplasticity and circadian genes. Valproate is thought to enhance GABAergic inhibition, modulate voltage-gated sodium channels, and inhibit histone deacetylases. Lamotrigine primarily acts as a use-dependent blocker of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting the release of glutamate. Second-generation antipsychotics (SGAs) used in bipolar disorder, such as quetiapine, lurasidone, and olanzapine, combine dopamine D₂ receptor antagonism with serotonin 5-HT_2A receptor antagonism, which may modulate dopamine release in specific pathways and contribute to mood stabilization.

Treatment Phases: Pharmacotherapy is conceptualized in three phases: acute mania/hypomania, acute depression, and maintenance. Drug choice and dosing differ per phase. For acute mania, lithium, valproate, or SGAs are first-line. For bipolar depression, evidence strongly supports quetiapine, lurasidone, lamotrigine (primarily for maintenance), and lithium. Antidepressants are used with extreme caution due to risks of inducing mania or rapid cycling.

3.3 Schizophrenia

Schizophrenia is a neurodevelopmental disorder with a complex pathophysiology involving multiple neurotransmitter systems and brain circuits. The dopamine hypothesis remains predominant, proposing hyperdopaminergia in subcortical mesolimbic pathways (contributing to positive symptoms) and hypodopaminergia in prefrontal mesocortical pathways (contributing to negative and cognitive symptoms). The glutamate hypothesis, centered on NMDA receptor hypofunction, provides an explanatory model for negative and cognitive symptoms and may drive secondary dopamine dysregulation. Structural and functional abnormalities are observed in cortical and subcortical regions, including the hippocampus and thalamus.

Mechanisms of Antipsychotic Drugs: All effective antipsychotics share antagonist activity at dopamine D₂ receptors. The degree of D₂ occupancy (≈65-80% for therapeutic effect, >80% increasing EPS risk) is a key determinant. First-generation antipsychotics (FGAs) are potent D₂ antagonists with varying affinities for other receptors, leading to a high incidence of EPS and hyperprolactinemia. Second-generation antipsychotics (SGAs) generally have lower affinity for D₂ receptors and higher affinity for serotonin 5-HT_2A receptors. This 5-HT_2A antagonism is believed to modulate dopamine release in the striatum, reducing EPS risk, and may contribute to benefits on negative symptoms. Many SGAs also have complex pharmacologies involving antagonism at muscarinic, histaminic, and α₁-adrenergic receptors, which largely account for their side effect profiles (e.g., weight gain, sedation, orthostasis).

Pharmacokinetics and Dosing: Most antipsychotics are well-absorbed orally, highly protein-bound, and metabolized extensively in the liver via cytochrome P450 enzymes (notably CYP2D6 and CYP3A4). Several are available in long-acting injectable (LAI) formulations (e.g., paliperidone palmitate, aripiprazole lauroxil), which provide sustained drug delivery over weeks to months, improving adherence and providing more stable plasma levels. The therapeutic response typically involves an initial reduction in positive symptoms over weeks, with potential further improvements in negative and cognitive symptoms over several months.

4. Clinical Significance

The translation of pharmacological principles into clinical practice is defined by a careful balance between efficacy and tolerability, with significant implications for patient outcomes and quality of life.

4.1 Relevance to Drug Therapy and Monitoring

Effective pharmacotherapy requires vigilant monitoring for therapeutic response and adverse effects. For ADHD medications, monitoring involves tracking symptom improvement on standardized scales, assessing impact on academic or occupational function, and monitoring growth in children (height, weight), cardiovascular parameters (heart rate, blood pressure), and potential for misuse or diversion. In bipolar disorder, therapeutic drug monitoring (TDM) is crucial for lithium (narrow therapeutic range 0.6-1.0 mEq/L for maintenance), requiring regular serum level checks, as well as monitoring of renal and thyroid function. For valproate, liver enzymes, complete blood count, and drug levels may be indicated. All mood stabilizers and antipsychotics require monitoring for metabolic syndrome components: weight, body mass index, waist circumference, fasting glucose or HbA1c, and lipid profile.

For antipsychotics in schizophrenia, monitoring extends beyond metabolic parameters to include assessment for movement disorders using tools like the Abnormal Involuntary Movement Scale (AIMS) for tardive dyskinesia, and monitoring for signs of neuroleptic malignant syndrome (NMS), a rare but life-threatening adverse reaction characterized by fever, muscle rigidity, autonomic instability, and altered mental status.

4.2 Practical Applications and Treatment Algorithms

Treatment follows evidence-based algorithms that prioritize efficacy, safety, and patient preference. In ADHD, stimulants are typically first-line due to superior effect sizes. The choice between methylphenidate and amphetamine preparations is often empirical, guided by individual response and tolerability. Non-stimulants are considered first-line in patients with substance use disorders, significant anxiety, or cardiac concerns. In bipolar I disorder, for acute mania, treatment often begins with an SGA or lithium/valproate, sometimes in combination. For maintenance, the agent that successfully treated the acute episode is often continued. In schizophrenia, treatment initiation involves an SGA or FGA, with selection influenced by the predominant symptom profile (e.g., SGAs with lower metabolic risk for negative symptoms, consideration of LAI early in treatment for non-adherent patients). Clozapine is reserved for treatment-resistant schizophrenia due to its superior efficacy but significant risk of agranulocytosis, requiring mandatory hematological monitoring.

4.3 Managing Comorbidity and Polypharmacy

Comorbidity is the rule rather than the exception. ADHD frequently co-occurs with anxiety, depression, and learning disorders. Bipolar disorder is commonly comorbid with anxiety and substance use disorders. Schizophrenia is associated with high rates of substance use, metabolic disorders, and cardiovascular disease. This comorbidity often necessitates polypharmacy, increasing the complexity of care. For instance, a patient with bipolar depression and comorbid ADHD may require a mood stabilizer, a cautious trial of a stimulant, and possibly an anxiolytic. Such combinations demand meticulous attention to pharmacodynamic interactions (e.g., additive sedation, QT_c prolongation) and pharmacokinetic interactions via shared metabolic pathways (e.g., CYP450 inhibition or induction).

5. Clinical Applications and Examples

The application of theoretical knowledge is best illustrated through clinical scenarios that require diagnostic reasoning and therapeutic decision-making.

5.1 Case Scenario: ADHD in a Young Adult

A 19-year-old university student presents with longstanding difficulties sustaining attention in lectures, chronic procrastination, poor organization, and forgetfulness. Symptoms were present in childhood but became more impairing with the increased academic demands of university. Physical examination is unremarkable; blood pressure is 118/76 mmHg, heart rate 72 bpm. A diagnosis of ADHD, predominantly inattentive presentation, is confirmed.

Pharmacotherapeutic Considerations: First-line treatment would involve a trial of a stimulant. Given the need for coverage throughout a full academic day, an extended-release formulation such as lisdexamfetamine or osmotic-release methylphenidate (OROS-MPH) would be appropriate. The initial dose is titrated upwards weekly based on response and tolerability. Key counseling points include the importance of taking the dose early in the day to avoid insomnia, the potential for decreased appetite (advising a good breakfast before the dose), and the need for regular monitoring of heart rate and blood pressure. If the patient reports significant anxiety as a side effect or has a history of substance misuse, a switch to a non-stimulant like atomoxetine could be considered, noting its slower onset of effect (4-8 weeks for full benefit).

5.2 Case Scenario: Bipolar I Disorder with Acute Mania

A 35-year-old individual is brought to the emergency department by family. The patient has not slept for 72 hours, is excessively talkative, has made several grandiose business plans, and maxed out credit cards. There is a past history of a major depressive episode. Mental status exam reveals pressured speech, flight of ideas, and grandiose delusions. A diagnosis of bipolar I disorder, current episode manic, is made.

Pharmacotherapeutic Plan: Acute management requires rapid control of symptoms to ensure safety. Treatment options include initiating an SGA like olanzapine or risperidone, which have a rapid onset of antimanic effect, or loading with valproate. Given the presence of psychotic features, an antipsychotic is often preferred initially. Agitation may require short-term use of a benzodiazepine like lorazepam. Once stabilized, the focus shifts to maintenance therapy. If the patient responded well to valproate, this could be continued long-term, with monitoring of serum levels, liver function, and hematological parameters. Alternatively, lithium could be initiated for long-term mood stabilization, requiring education on maintaining consistent fluid and salt intake and the necessity of regular blood tests.

5.3 Case Scenario: Treatment-Resistant Schizophrenia

A 42-year-old patient with a 20-year history of schizophrenia has persistent auditory hallucinations and social withdrawal despite adequate trials of two different antipsychotics (risperidone and olanzapine) at therapeutic doses for sufficient durations. The patient has significant metabolic side effects from previous treatments.

Problem-Solving Approach: This presentation meets common criteria for treatment-resistant schizophrenia. The next evidence-based step is a trial of clozapine. Prior to initiation, a baseline absolute neutrophil count (ANC) must be obtained. The patient and family require extensive education on the risk of agranulocytosis (1-2%) and the mandatory weekly, then bi-weekly, then monthly blood monitoring regimen. Clozapine is started at a very low dose (12.5 mg) and titrated slowly to minimize risks of sedation, hypotension, and seizures. Concurrent medications with anticholinergic or myelosuppressive effects should be reviewed. If successful, clozapine often provides superior efficacy for both positive and negative symptoms. For patients who cannot tolerate or fail clozapine, strategies include combining another antipsychotic with clozapine or using high-potency SGAs like paliperidone, though evidence is less robust.

6. Summary and Key Points

This chapter has provided a comprehensive overview of the pharmacology underlying three major psychiatric disorders. The following points encapsulate the essential knowledge.

• Neurobiological Foundations: ADHD pathophysiology centers on catecholamine dysregulation in prefrontal circuits; bipolar disorder involves dysregulated intracellular signaling and kindling; schizophrenia is characterized by dopamine and glutamate system dysfunction across multiple brain networks.
• Mechanisms of Action: Stimulants increase synaptic dopamine/noradrenaline via reuptake inhibition or release. Mood stabilizers like lithium modulate second messenger systems. Antipsychotics primarily exert therapeutic effects through D₂ receptor antagonism, with SGAs offering a broader receptor profile that modifies side effect risks and may influence negative symptoms.
• Clinical Pharmacokinetics: Formulation technology (ER, LAI) is critical for adherence and stable effect. Metabolism via CYP450 enzymes (especially 2D6 and 3A4) is common, creating significant potential for drug-drug interactions.
• Therapeutic Monitoring: Essential monitoring includes growth and cardiovascular parameters for ADHD drugs; serum levels, renal, and thyroid function for lithium; metabolic parameters (weight, glucose, lipids) for SGAs and some mood stabilizers; and hematological parameters for clozapine.
• Treatment Resistance: For ADHD, switching stimulant classes or using non-stimulants is considered. In bipolar disorder, optimizing mood stabilizer levels or using combination therapy is key. In schizophrenia, clozapine remains the gold-standard treatment for resistance, necessitating rigorous safety monitoring.

Clinical Pearls:

• Stimulant efficacy in ADHD is among the highest of any psychopharmacological intervention, but careful titration and monitoring are required.
• Lithium has a narrow therapeutic index; factors like dehydration, NSAIDs, and thiazide diuretics can increase serum levels to the toxic range.
• Metabolic side effects of SGAs (weight gain, diabetes, dyslipidemia) are a major cause of long-term morbidity and non-adherence; proactive monitoring and lifestyle intervention are mandatory.
• Clozapine, despite its risks, is the only medication with proven superior efficacy in treatment-resistant schizophrenia and is associated with reduced mortality, including from suicide.
• Polypharmacy is common but should be justified by clear clinical targets, with ongoing efforts to minimize the medication burden and interaction risk.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.